Stölzel, F., Stelljes, M., Beelen, D. W., Markiewicz, M., Reményi, P., Luft, T., Ciceri, F., Wagner-Drouet, E.-M., Junghanss, C., Scheid, C., Patriarca, F., Socié, G., Hilgendorf, I., Rambaldi, A., Schaefer-Eckart, K., Russo, D., Wulf, G., Glass, B., Labussiere-Wallet, H., Stuhler, G., Bieniaszewska, M., Casper, J., Holler, E., Benedetti, F., Iori, A. P., Kunadt, D., Mihajlović, J., Schild, B., Khan, I., Li, X. and Bethge, W. (2020) “GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial”, Haematologica. Pavia, Italy. doi: 10.3324/haematol.2025.288770.